A more recent publication involving a larger cohort (n = 100 for PDAC, n = 30 for HC, and n = 16 for IPMN) identified vimentin+ CTCs (v+ CTCs) in 76% of PDAC, 6.6% of HC, and 31% of IPMN samples [177]. Here, VIM is linked to pancreatic intraductal papillary-mucinous neoplasm.